{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:38:39Z","timestamp":1792748319432,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K06882"],"award-info":[{"award-number":["21K06882"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K06458"],"award-info":[{"award-number":["23K06458"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gastric cancer with peritoneal dissemination (PD) has a dismal prognosis, and current treatments have shown little efficacy. CLDN18.2-targeted therapies have shown promising efficacy against gastric cancers that express high levels of CLDN18. Because of the limited information regarding CLDN18.2 status in PD, we analyzed PD-positive gastric cancers for CLDN18 status in both primary and PD, along with HER2 and PD-L1 combined positive score (CPS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Immunohistochemical analyses were performed on 84 gastric cancer cases using paired primary and PD tissue samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At 40% cut-off, CLDN18 was positive in 57% (48\/84) primary tumors and in 44% (37\/84) PDs. At 75% cut-off, 28.6% (24\/84) primary tumors and 20.2% (17\/84) PDs were CLDN18-positive. The concordance rate between primary tumors and PD was 79.8% at 40% cut-off and 75% at 75% cut-off. When comparing biopsy and surgical specimens, the concordance rates were 87.5% at 40% cut-off and 81.3% at 75% cut-off. Within a tumor, the superficial area tended to have a higher CLDN18-positive rate than the invasive front (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001). Although HER2 -positivity was only 11.9% in this cohort, CLDN18 positivity in HER2-negative tumors (n\u2009=\u200974) was relatively high: 60.8% at 40% cut-off and 28.4% at 75% cut-off. Among double-negative (HER2\u2009\u2212\u2009and PD-L1 CPS\u2009&lt;\u20091) tumors, CLDN18 positivity was 67.6% at 40% cut-off and 26.5% at 75% cut-off.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CLDN18 expression is generally maintained in PD and is relatively high even in double-negative tumors, making it a promising therapeutic target for PD-positive gastric cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10120-024-01505-6","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T16:30:16Z","timestamp":1715272216000},"page":"802-810","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination"],"prefix":"10.1007","volume":"27","author":[{"given":"Haruki","family":"Ogawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1763-8380","authenticated-orcid":false,"given":"Tetsuo","family":"Ushiku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"1505_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"1505_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10120-016-0658-5","volume":"20","author":"M Inoue","year":"2017","unstructured":"Inoue M. Changing epidemiology of Helicobacter pylori in Japan. Gastric Cancer. 2017;20:3\u20137. https:\/\/doi.org\/10.1007\/s10120-016-0658-5.","journal-title":"Gastric Cancer"},{"key":"1505_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00620-7","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang Y-J, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. 2023. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7.","journal-title":"The Lancet"},{"key":"1505_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02465-7","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"key":"1505_CR5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin U, T\u00fcreci Manikhas G, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32:609\u201319. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.005.","journal-title":"Ann Oncol"},{"key":"1505_CR6","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1128\/mcb.21.21.7380-7390.2001","volume":"21","author":"T Niimi","year":"2001","unstructured":"Niimi T, Nagashima K, Ward JM, et al. claudin-18, a novel downstream target gene for the T\/EBP\/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol Cell Biol. 2001;21:7380\u201390. https:\/\/doi.org\/10.1128\/mcb.21.21.7380-7390.2001.","journal-title":"Mol Cell Biol"},{"key":"1505_CR7","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14:7624\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1547.","journal-title":"Clin Cancer Res"},{"key":"1505_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074757","author":"T Oshima","year":"2013","unstructured":"Oshima T, Shan J, Okugawa T, et al. Down-regulation of claudin-18 is associated with the proliferative and invasive potential of gastric cancer at the invasive front. PLoS One. 2013. https:\/\/doi.org\/10.1371\/journal.pone.0074757.","journal-title":"PLoS One"},{"key":"1505_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ijsu.2013.11.022","volume":"12","author":"KH Jun","year":"2014","unstructured":"Jun KH, Kim JH, Jung JH, Choi HJ, Chin HM. Expression of claudin-7 and loss of claudin-18 correlate with poor prognosis in gastric cancer. Int J Surg. 2014;12:156\u201362. https:\/\/doi.org\/10.1016\/j.ijsu.2013.11.022.","journal-title":"Int J Surg"},{"key":"1505_CR10","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/jjco\/hyz068","volume":"49","author":"C Rohde","year":"2019","unstructured":"Rohde C, Yamaguchi R, Mukhina S, Sahin U, Itoh K, T\u00fcreci \u00d6. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Jpn J Clin Oncol. 2019;49:870\u20136. https:\/\/doi.org\/10.1093\/jjco\/hyz068.","journal-title":"Jpn J Clin Oncol"},{"key":"1505_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/cncy.22688","volume":"131","author":"J Dai","year":"2023","unstructured":"Dai J, Zheng H, Jin J, Cheng Y, Xu H. Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: a comparative study with tissue specimens. Cancer Cytopathol. 2023;131:365\u201372. https:\/\/doi.org\/10.1002\/cncy.22688.","journal-title":"Cancer Cytopathol"},{"key":"1505_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","volume":"64","author":"P Lauren","year":"1965","unstructured":"Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31\u201349. https:\/\/doi.org\/10.1111\/apm.1965.64.1.31.","journal-title":"Acta Pathol Microbiol Scand"},{"key":"1505_CR13","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","volume":"35","author":"AN Bartley","year":"2017","unstructured":"Bartley AN, Washington MK, Colasacco C, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the college of american pathologists, American society for clinical pathology, and the American society of clinical oncology. J Clin Oncol. 2017;35:446\u201364. https:\/\/doi.org\/10.1200\/JCO.2016.69.4836.","journal-title":"J Clin Oncol"},{"key":"1505_CR14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","volume":"143","author":"K Kulangara","year":"2019","unstructured":"Kulangara K, Zhang N, Corigliano E, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143:330\u20137. https:\/\/doi.org\/10.5858\/arpa.2018-0043-OA.","journal-title":"Arch Pathol Lab Med"},{"key":"1505_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet. 2021;398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"The Lancet"},{"key":"1505_CR16","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/j.1349-7006.2007.00490.x","volume":"98","author":"Y Matsuda","year":"2007","unstructured":"Matsuda Y, Semba S, Ueda J, et al. Gastric and intestinal claudin expression at the invasive front of gastric carcinoma. Cancer Sci. 2007;98:1014\u20139. https:\/\/doi.org\/10.1111\/j.1349-7006.2007.00490.x.","journal-title":"Cancer Sci"},{"key":"1505_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","volume":"121","author":"I Coati","year":"2019","unstructured":"Coati I, Lotz G, Fanelli GN, et al. Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. Br J Cancer. 2019;121:257\u201363. https:\/\/doi.org\/10.1038\/s41416-019-0508-4.","journal-title":"Br J Cancer"},{"key":"1505_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00428-014-1597-3","volume":"465","author":"H Yoshida","year":"2014","unstructured":"Yoshida H, Yamamoto N, Taniguchi H, et al. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. Virchows Arch. 2014;465:145\u201354. https:\/\/doi.org\/10.1007\/s00428-014-1597-3.","journal-title":"Virchows Arch"},{"key":"1505_CR19","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/annonc\/mds622","volume":"24","author":"AFC Okines","year":"2013","unstructured":"Okines AFC, Thompson LC, Cunningham D, et al. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol. 2013;24:1253\u201361. https:\/\/doi.org\/10.1093\/annonc\/mds622.","journal-title":"Ann Oncol"},{"key":"1505_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13000-017-0616-5","volume":"12","author":"C Xu","year":"2017","unstructured":"Xu C, Liu Y, Ge X, et al. Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer. Diagn Pathol. 2017;12:41. https:\/\/doi.org\/10.1186\/s13000-017-0616-5.","journal-title":"Diagn Pathol"},{"issue":"35","key":"1505_CR21","doi-asserted-by":"publisher","first-page":"38372","DOI":"10.18632\/oncotarget.5368","volume":"6","author":"S Ahn","year":"2015","unstructured":"Ahn S, Ahn S, Van Vrancken M, et al. Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens. Oncotarget. 2015;6(35):38372\u201380. https:\/\/doi.org\/10.18632\/oncotarget.5368.","journal-title":"Oncotarget"},{"key":"1505_CR22","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10120-015-0502-3","volume":"19","author":"N Tominaga","year":"2016","unstructured":"Tominaga N, Gotoda T, Hara M, et al. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. Gastric Cancer. 2016;19:553\u201360. https:\/\/doi.org\/10.1007\/s10120-015-0502-3.","journal-title":"Gastric Cancer"},{"key":"1505_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11111095","author":"A Pellino","year":"2021","unstructured":"Pellino A, Brignola S, Riello E, et al. Association of cldn18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. J Pers Med. 2021. https:\/\/doi.org\/10.3390\/jpm11111095.","journal-title":"J Pers Med"},{"key":"1505_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100762","author":"Y Kubota","year":"2023","unstructured":"Kubota Y, Kawazoe A, Mishima S, et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open. 2023. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100762.","journal-title":"ESMO Open"},{"key":"1505_CR25","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","volume":"18","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Bang YJ, Feng-yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18:476\u201384. https:\/\/doi.org\/10.1007\/s10120-014-0402-y.","journal-title":"Gastric Cancer"},{"key":"1505_CR26","doi-asserted-by":"publisher","first-page":"408","DOI":"10.5230\/jgc.2020.20.e33","volume":"20","author":"SR Kim","year":"2020","unstructured":"Kim SR, Shin K, Park JM, Lee HH, Song KY, Lee SH, et al. Clinical significance of CLDN18.2 expression in metastatic diffuse-type gastric cancer. J Gastric Cancer. 2020;20:408\u201320. https:\/\/doi.org\/10.5230\/jgc.2020.20.e33.","journal-title":"J Gastric Cancer"},{"key":"1505_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, \u00d6zg\u00fcro\u011flu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. The Lancet. 2018;392:123\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(18)31257-1.","journal-title":"The Lancet"},{"key":"1505_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1356144","author":"X Xing","year":"2018","unstructured":"Xing X, Guo J, Wen X, Ding G, Li B, Dong B, et al. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. Oncoimmunology. 2018. https:\/\/doi.org\/10.1080\/2162402X.2017.1356144.","journal-title":"Oncoimmunology"},{"key":"1505_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.117247","author":"PX He","year":"2020","unstructured":"He PX, Ma ZL, Han H, Zhang XY, Niu SH, Du LN, et al. Expression of programmed death ligand 1 (PD-L1) is associated with metastasis and differentiation in gastric cancer. Life Sci. 2020. https:\/\/doi.org\/10.1016\/j.lfs.2019.117247.","journal-title":"Life Sci"},{"key":"1505_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1634\/theoncologist.2018-0221","volume":"24","author":"L Fashoyin-Aje","year":"2019","unstructured":"Fashoyin-Aje L, Donoghue M, Chen H, et al. FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist. 2019;24:103\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2018-0221.","journal-title":"Oncologist"},{"key":"1505_CR31","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","volume":"12","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol. 2017;12:208\u201322. https:\/\/doi.org\/10.1016\/j.jtho.2016.11.2228.","journal-title":"J Thorac Oncol"},{"key":"1505_CR32","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/annonc\/mdy014","volume":"29","author":"J Adam","year":"2018","unstructured":"Adam J, Le Stang N, Rouquette I, et al. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Ann Oncol. 2018;29:953\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdy014.","journal-title":"Ann Oncol"},{"key":"1505_CR33","doi-asserted-by":"publisher","first-page":"661","DOI":"10.4143\/crt.2019.718","volume":"52","author":"Y Park","year":"2020","unstructured":"Park Y, Koh J, Na HY, et al. PD-L1 testing in gastric cancer by the combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant cut-offs. Cancer Res Treat. 2020;52:661\u201370. https:\/\/doi.org\/10.4143\/crt.2019.718.","journal-title":"Cancer Res Treat"},{"key":"1505_CR34","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10120-014-0417-4","volume":"18","author":"T Saito","year":"2015","unstructured":"Saito T, Nakanishi H, Mochizuki Y, Ito S, Ito Y, Misawa K, et al. Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer. Gastric Cancer. 2015;18:711\u20139. https:\/\/doi.org\/10.1007\/s10120-014-0417-4.","journal-title":"Gastric Cancer"},{"key":"1505_CR35","doi-asserted-by":"publisher","first-page":"13345","DOI":"10.1007\/s00432-023-05142-x","volume":"149","author":"DHW Liu","year":"2023","unstructured":"Liu DHW, Grabsch HI, Gloor B, Langer R, Dislich B. Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases. J Cancer Res Clin Oncol. 2023;149:13345\u201352. https:\/\/doi.org\/10.1007\/s00432-023-05142-x.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-024-01505-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-024-01505-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-024-01505-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T10:06:04Z","timestamp":1719050764000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-024-01505-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1505"],"URL":"https:\/\/doi.org\/10.1007\/s10120-024-01505-6","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"assertion":[{"value":"6 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest related to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed according to the Declaration of Helsinki, and the study protocol was approved by the institutional review board (approval number G3521). The requirement to obtain written informed consent was waived because this was a retrospective study using existing pathology slides and formalin-fixed, paraffin-embedded blocks. Instead, we used an opt-out approach to provide participants with an informed choice about participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}